{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:18:18Z","timestamp":1790201898805,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T00:00:00Z","timestamp":1538697600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010156","name":"Netherlands Leprosy Relief","doi-asserted-by":"publisher","award":["none"],"award-info":[{"award-number":["none"]}],"id":[{"id":"10.13039\/100010156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12879-018-3402-4","type":"journal-article","created":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T11:54:13Z","timestamp":1538740453000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["An enhanced regimen as post-exposure chemoprophylaxis for leprosy: PEP++"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6943-1712","authenticated-orcid":false,"given":"Liesbeth F","family":"Mieras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna T","family":"Taal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim H","family":"van Brakel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Cambau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R","family":"Saunderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W Cairns S","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cita Rosita S","family":"Prakoeswa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Astari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M","family":"Scollard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dejair Caitano","family":"do Nascimento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Grosset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemanta K","family":"Kar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinzo","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Gillini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos C L","family":"Virmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke G G","family":"Sturkenboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,5]]},"reference":[{"key":"3402_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s13071-015-1143-4","volume":"8","author":"DJ Blok","year":"2015","unstructured":"Blok DJ, De Vlas SJ, Richardus JH. Global elimination of leprosy by 2020: are we on track? Parasit Vectors. 2015;8:548. https:\/\/doi.org\/10.1186\/s13071-015-1143-4 .","journal-title":"Parasit Vectors"},{"key":"3402_CR2","unstructured":"WHO | Leprosy. WHO. 2017. http:\/\/www.who.int\/mediacentre\/factsheets\/fs101\/en\/ . Accessed 30 May 2017."},{"key":"3402_CR3","unstructured":"WHO. Accelerating towards a leprosy-free world. 2017. http:\/\/apps.who.int\/iris\/bitstream\/10665\/254907\/1\/9789290225492-eng.pdf . Accessed 18 Dec 2017."},{"key":"3402_CR4","first-page":"112","volume":"69","author":"IA Cree","year":"1998","unstructured":"Cree IA, Smith WC. Leprosy transmission and mucosal immunity: towards eradication? Lepr Rev. 1998;69:112\u201321 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9715595 . Accessed 30 May 2017.","journal-title":"Lepr Rev"},{"key":"3402_CR5","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1017\/S0950268803001079","volume":"131","author":"D Beyene","year":"2003","unstructured":"Beyene D, Aseffa A, Harboe M, Kidane D, Macdonald M, Klatser PR, et al. Nasal carriage of Mycobacterium leprae DNA in healthy individuals in Lega Robi village, Ethiopia. Epidemiol Infect. 2003;131:841\u20138. https:\/\/doi.org\/10.1017\/S0950268803001079 .","journal-title":"Epidemiol Infect"},{"key":"3402_CR6","doi-asserted-by":"crossref","first-page":"142","DOI":"10.47276\/lr.86.2.142","volume":"86","author":"MW Bratschi","year":"2015","unstructured":"Bratschi MW, Steinmann P, Wickenden A, Gillis TP. Current knowledge on Mycobacterium leprae transmission\u00a0: a systematic literature review \u2020. Lepr Rev. 2015;86:142\u201355 https:\/\/www.lepra.org.uk\/platforms\/lepra\/files\/lr\/June15\/Lep142-155.pdf . Accessed 7 Dec 2017.","journal-title":"Lepr Rev"},{"key":"3402_CR7","first-page":"91","volume":"146","author":"PE Fine","year":"1997","unstructured":"Fine PE, Sterne JA, Ponnighaus JM, Bliss L, Saui J, Chihana A, et al. Household and dwelling contact as risk factors for leprosy in northern Malawi. AmJEpidemiol. 1997;146:91\u2013102.","journal-title":"AmJEpidemiol"},{"key":"3402_CR8","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1086\/499278","volume":"193","author":"FJ Moet","year":"2006","unstructured":"Moet FJ, Pahan D, Schuring RP, Oskam L, Richardus JH. Physical distance, genetic relationship, age, and leprosy classification are independent risk factors for leprosy in contacts of patients with leprosy. J Infect Dis. 2006;193:346\u201353.","journal-title":"J Infect Dis"},{"key":"3402_CR9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1053\/jinf.2000.0698","volume":"41","author":"CM Smith","year":"2000","unstructured":"Smith CM, Smith WC, Davey T, Remy J, Ramaprasad P, Fernando A, et al. Chemoprophylaxis is effective in the prevention of leprosy in endemic countries: a systematic review and meta-analysis. MILEP2 Study Group. Mucosal Immunology of Leprosy. J Infect. 2000;41:137\u201342. https:\/\/doi.org\/10.1053\/jinf.2000.0698 .","journal-title":"J Infect"},{"key":"3402_CR10","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1590\/S1020-49892009001000009","volume":"26","author":"L Reveiz","year":"2009","unstructured":"Reveiz L, Buend\u00eda JA, T\u00e9llez D. Chemoprophylaxis in contacts of patients with leprosy: systematic review and meta-analysis. Pan Am J public Heal. 2009;26:341\u20139. https:\/\/doi.org\/10.1590\/S1020-49892009001000009 .","journal-title":"Pan Am J public Heal"},{"key":"3402_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7883\/yoken.63.1","volume":"63","author":"M Matsuoka","year":"2010","unstructured":"Matsuoka M. Drug resistance in leprosy. Jpn J Infect Dis. 2010;63:1\u20137.","journal-title":"Jpn J Infect Dis"},{"key":"3402_CR12","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1136\/bmj.39500.885752.BE","volume":"336","author":"FJ Moet","year":"2008","unstructured":"Moet FJ, Pahan D, Oskam L, Richardus JH. Effectiveness of single dose rifampicin in preventing leprosy in close contacts of patients with newly diagnosed leprosy: cluster randomised controlled trial. BMJ. 2008;336:761\u20134. https:\/\/doi.org\/10.1136\/bmj.39500.885752.BE .","journal-title":"BMJ"},{"key":"3402_CR13","first-page":"S26","volume":"67","author":"K Tin","year":"1999","unstructured":"Tin K. Population screening and chemoprophylaxis for household contacts of leprosy patients in the Republic of the Marshall Islands. IntJLeprOther MycobactDis. 1999;67:S26\u20139 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10700934 . Accessed 17 Oct 2017.","journal-title":"IntJLeprOther MycobactDis."},{"issue":"Suppl","key":"3402_CR14","first-page":"S21","volume":"71","author":"C Diletto","year":"2000","unstructured":"Diletto C, Blanc L, Levy L. Leprosy chemoprophylaxis in Micronesia. Lepr Rev. 2000;71(Suppl):S21\u20133 discussion S24\u20135.","journal-title":"Lepr Rev"},{"key":"3402_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005399","volume":"11","author":"L Gillini","year":"2017","unstructured":"Gillini L, Cooreman E, Wood T, Pemmaraju VR, Saunderson P. Global practices in regard to implementation of preventive measures for leprosy. PLoS Negl Trop Dis. 2017;11:e0005399. https:\/\/doi.org\/10.1371\/journal.pntd.0005399 .","journal-title":"PLoS Negl Trop Dis"},{"key":"3402_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-013633","volume":"6","author":"T Barth-Jaeggi","year":"2016","unstructured":"Barth-Jaeggi T, Steinmann P, Mieras L, van Brakel W, Richardus JH, Tiwari A, et al. Leprosy post-exposure prophylaxis (LPEP) programme: study protocol for evaluating the feasibility and impact on case detection rates of contact tracing and single dose rifampicin. BMJ Open. 2016;6:e013633. https:\/\/doi.org\/10.1136\/bmjopen-2016-013633 .","journal-title":"BMJ Open"},{"key":"3402_CR17","volume-title":"Emerging evidence from the leprosy post-exposure prophylaxis project: an overview. Beijing","author":"P Steinmann","year":"2016","unstructured":"Steinmann P, Barth-Jaeggi T, Cavaliero A, Vander Plaetse B, Tiwari A. Richardus JH. 19th international leprosy congress. In: Emerging evidence from the leprosy post-exposure prophylaxis project: an overview. Beijing; 2016."},{"key":"3402_CR18","unstructured":"WHO | Effectiveness of MDT: FAQ. WHO. 2016. http:\/\/www.who.int\/lep\/mdt\/effectiveness\/en\/ . Accessed 10 July 2017."},{"key":"3402_CR19","unstructured":"World Health Organization. Expert Committee on Leprosy. Eigth Report. World Health Organization Technical Report Series. 2012;978(968):1\u201361. http:\/\/www.who.int\/about\/licensing\/copyright_form\/en\/index.html ."},{"key":"3402_CR20","first-page":"446","volume":"21","author":"CC Shepard","year":"1972","unstructured":"Shepard CC, Levy L, Fasal P. Rapid bactericidal effect of rifampin on Mycobacterium leprae. AmJTropMedHyg. 1972;21:446\u20139.","journal-title":"AmJTropMedHyg"},{"key":"3402_CR21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/0041-3879(80)90060-4","volume":"61","author":"M Zierski","year":"1980","unstructured":"Zierski M, Bek E. Side-effects of drug regimens used in short-course chemotherapy for pulmonary tuberculosis. A controlled clinical study. Tubercle. 1980;61:41\u20139. https:\/\/doi.org\/10.1016\/0041-3879(80)90060-4 .","journal-title":"Tubercle"},{"key":"3402_CR22","first-page":"7","volume":"49","author":"MJ Colston","year":"1978","unstructured":"Colston MJ, Hilson GR, Banerjee DK. The & quot;proportional bactericidal test": a method for assessing bactericidal activity in drugs against Mycobacterium leprae in mice. Lepr Rev. 1978;49:7\u201315 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/347206 . Accessed 10 May 2017.","journal-title":"Lepr Rev"},{"key":"3402_CR23","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1128\/AAC.44.10.2919-2921.2000","volume":"44","author":"S Consigny","year":"2000","unstructured":"Consigny S, Bentoucha A, Bonnafous P, Grosset J, Ji B. Bactericidal activities of HMR 3647, moxifloxacin, and rifapentine against Mycobacterium leprae in mice. Antimicrob Agents Chemother. 2000;44:2919\u201321. https:\/\/doi.org\/10.1128\/AAC.44.10.2919-2921.2000 .","journal-title":"Antimicrob Agents Chemother"},{"key":"3402_CR24","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1164\/rccm.200201-047OC","volume":"165","author":"NN Bock","year":"2002","unstructured":"Bock NN, Sterling TR, Hamilton CD, Pachucki C, Wang YC, Conwell DS, et al. A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment. Am J Respir Crit Care Med. 2002;165:1526\u201330. https:\/\/doi.org\/10.1164\/rccm.200201-047OC .","journal-title":"Am J Respir Crit Care Med"},{"key":"3402_CR25","doi-asserted-by":"publisher","first-page":"4331","DOI":"10.1128\/AAC.00912-12","volume":"56","author":"IM Rosenthal","year":"2012","unstructured":"Rosenthal IM, Tasneen R, Peloquin CA, Zhang M, Almeida D, Mdluli KE, et al. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob Agents Chemother. 2012;56:4331\u201340. https:\/\/doi.org\/10.1128\/AAC.00912-12 .","journal-title":"Antimicrob Agents Chemother"},{"key":"3402_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002404","volume":"7","author":"GL Davis","year":"2013","unstructured":"Davis GL, Ray NA, Lahiri R, Gillis TP, Krahenbuhl JL, Williams DL, et al. Molecular assays for determining Mycobacterium leprae viability in tissues of experimentally infected mice. PLoS Negl Trop Dis. 2013;7:e2404. https:\/\/doi.org\/10.1371\/journal.pntd.0002404 .","journal-title":"PLoS Negl Trop Dis"},{"key":"3402_CR27","first-page":"241","volume":"32","author":"JL Arbiser","year":"1995","unstructured":"Arbiser JL, Moschella SL. Clofazimine: a review of its medical uses and mechanisms of action. JAmAcadDermatol. 1995;32:241\u20137.","journal-title":"JAmAcadDermatol"},{"key":"3402_CR28","doi-asserted-by":"publisher","first-page":"769","DOI":"10.4269\/ajtmh.1968.17.769","volume":"17","author":"CC Shepard","year":"1968","unstructured":"Shepard CC, Levy L, Fasal P. The death of Mycobacterium leprae during treatment with 4,4\u2032-diaminodiphenylsulfone (DDS). Initial rate in patients Am J Trop Med Hyg. 1968;17:769\u201375. https:\/\/doi.org\/10.4269\/ajtmh.1968.17.769 .","journal-title":"Initial rate in patients Am J Trop Med Hyg"},{"key":"3402_CR29","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1128\/AAC.01162-07","volume":"52","author":"FEF Pardillo","year":"2008","unstructured":"Pardillo FEF, Burgos J, Fajardo TT, Dela Cruz E, Abalos RM, Paredes RMD, et al. Powerful bactericidal activity of moxifloxacin in human leprosy. Antimicrob Agents Chemother. 2008;52:3113\u20137. https:\/\/doi.org\/10.1128\/AAC.01162-07 .","journal-title":"Antimicrob Agents Chemother"},{"key":"3402_CR30","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1086\/516119","volume":"25","author":"JE Burkhardt","year":"1997","unstructured":"Burkhardt JE, Walterspiel JN, Schaad UB. Quinolone Arthropathy in animals versus children. Clin Infect Dis. 1997;25:1196\u2013204. https:\/\/doi.org\/10.1086\/516119 .","journal-title":"Clin Infect Dis"},{"key":"3402_CR31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1093\/jac\/43.suppl_2.91","volume":"43","author":"E von Keutz","year":"1999","unstructured":"von Keutz E, Schl\u00fcter G. Preclinical safety evaluation of moxifloxacin, a novel fluoroquinolone. J Antimicrob Chemother. 1999;43:91\u2013100. https:\/\/doi.org\/10.1093\/jac\/43.suppl_2.91 .","journal-title":"J Antimicrob Chemother"},{"key":"3402_CR32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ijid.2017.05.003","volume":"60","author":"P Xu","year":"2017","unstructured":"Xu P, Chen H, Xu J, Wu M, Zhu X, Wang F, et al. Moxifloxacin is an effective and safe candidate agent for tuberculosis treatment: a meta-analysis. Int J Infect Dis. 2017;60:35\u201341. https:\/\/doi.org\/10.1016\/j.ijid.2017.05.003 .","journal-title":"Int J Infect Dis"},{"key":"3402_CR33","first-page":"24S","volume":"87","author":"S Flor","year":"1989","unstructured":"Flor S. Pharmacokinetics of ofloxacin. An overview Am J Med. 1989;87:24S\u201330S http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/2603892 . Accessed 13 Jun 2018.","journal-title":"An overview Am J Med"},{"key":"3402_CR34","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1358\/dot.2000.36.4.570201","volume":"36","author":"PA Moise","year":"2000","unstructured":"Moise PA, Birmingham MC, Schentag JJ. Pharmacokinetics and metabolism of moxifloxacin. Drugs of Today. 2000;36:229\u201344. https:\/\/doi.org\/10.1358\/dot.2000.36.4.570201 .","journal-title":"Drugs of Today"},{"key":"3402_CR35","first-page":"568","volume":"62","author":"RH Gelber","year":"1994","unstructured":"Gelber RH, Murray LP, Siu P, Tsang M, Rea TH. Efficacy of minocycline in single dose and at 100 mg twice daily for lepromatous leprosy. IntJLeprOther MycobactDis. 1994;62:568\u201373 http:\/\/ila.ilsl.br\/pdfs\/v62n4a10.pdf . Accessed 10 May 2017.","journal-title":"IntJLeprOther MycobactDis"},{"key":"3402_CR36","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1128\/AAC.35.3.579","volume":"35","author":"B Ji","year":"1991","unstructured":"Ji B, Perani EG, Grosset JH. Effectiveness of clarithromycin and minocycline alone and in combination against experimental Mycobacterium leprae infection in mice. Antimicrob Agents Chemother. 1991;35:579\u201381. https:\/\/doi.org\/10.1128\/AAC.35.3.579 .","journal-title":"Antimicrob Agents Chemother"},{"key":"3402_CR37","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1097\/00006454-198605000-00049","volume":"254","author":"SC Poliak","year":"1985","unstructured":"Poliak SC, DiGiovanna JJ, Gross EG, Gantt G, Peck GL. Minocycline-associated tooth discoloration in young adults. JAMA. 1985;254:2930\u20132. https:\/\/doi.org\/10.1097\/00006454-198605000-00049 .","journal-title":"JAMA"},{"key":"3402_CR38","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jaad.2009.05.046","volume":"62","author":"KK Shaughnessy","year":"2010","unstructured":"Shaughnessy KK, Bouchard SM, Mohr MR, Herre JM, Salkey KS. Minocycline-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome with persistent myocarditis. J Am Acad Dermatol. 2010;62:315\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2009.05.046 .","journal-title":"J Am Acad Dermatol"},{"key":"3402_CR39","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/infdis\/168.1.188","volume":"168","author":"B Ji","year":"1993","unstructured":"Ji B, Jamet P, Perani EG, Bobin P, Grosset JH, Ji B, et al. Powerful bactericidal activities of clarithromycin and minocycline against Mycobacterium leprae in Lepromatous leprosy. J Infect Dis. 1993;168:188\u201390. https:\/\/doi.org\/10.1093\/infdis\/168.1.188 .","journal-title":"J Infect Dis"},{"key":"3402_CR40","first-page":"25","volume":"88","author":"MS Bader","year":"2013","unstructured":"Bader MS, McKinsey DS. Postexposure prophylaxis for common infectious diseases. Am Fam Physician. 2013;88:25\u201332 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23939603 . Accessed 31 May 2018.","journal-title":"Am Fam Physician"},{"key":"3402_CR41","doi-asserted-by":"publisher","first-page":"12106","DOI":"10.1073\/pnas.94.22.12106","volume":"94","author":"S Bonhoeffer","year":"1997","unstructured":"Bonhoeffer S, Lipsitch M, Levin BR. Evaluating treatment protocols to prevent antibiotic resistance. Proc Natl Acad Sci U S A. 1997;94:12106\u201311 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9342370 . Accessed 5 June 2017.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3402_CR42","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/S0140-6736(76)92071-7","volume":"308","author":"R Jacobson","year":"1976","unstructured":"Jacobson R, Hastings R. Rifampin-resistant leprosy. Lancet. 1976;308:1304\u20135.","journal-title":"Lancet"},{"key":"3402_CR43","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0140-6736(05)60888-4","volume":"349","author":"E Cambau","year":"1997","unstructured":"Cambau E, Perani E, Guillemin I, Jamet P, Ji B. Multidrug-resistance to dapsone, rifampicin, and ofloxacin in Mycobacterium leprae. Lancet (London, England). 1997;349:103\u20134. https:\/\/doi.org\/10.1016\/S0140-6736(05)60888-4 .","journal-title":"Lancet (London, England)"},{"key":"3402_CR44","doi-asserted-by":"publisher","unstructured":"Cambau E, Saunderson P, Matsuoka M, Cole ST, Kai M, Suffys P, et al. Antimicrobial resistance in leprosy: results of the first prospective open survey conducted by a WHO surveillance network for the period 2009-15. Clin Microbiol Infect. 2018;0. https:\/\/doi.org\/10.1016\/j.cmi.2018.02.022 .","DOI":"10.1016\/j.cmi.2018.02.022"},{"key":"3402_CR45","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1745-6673-1-9","volume":"1","author":"SG Kosseifi","year":"2006","unstructured":"Kosseifi SG, Guha B, Nassour DN, Chi DS, Krishnaswamy G. The Dapsone hypersensitivity syndrome revisited: a potentially fatal multisystem disorder with prominent hepatopulmonary manifestations. J Occup Med Toxicol. 2006;1:9. https:\/\/doi.org\/10.1186\/1745-6673-1-9 .","journal-title":"J Occup Med Toxicol"},{"key":"3402_CR46","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1128\/AAC.42.5.1115","volume":"42","author":"B Ji","year":"1998","unstructured":"Ji B, Sow S, Perani E, Lienhardt C, Diderot V, Grosset J. Bactericidal activity of a single-dose combination of ofloxacin plus minocycline, with or without rifampin, against Mycobacterium leprae in mice and in lepromatous patients. Antimicrob Agents Chemother. 1998;42:1115\u201320 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9593137 . Accessed 17 Oct 2017.","journal-title":"Antimicrob Agents Chemother"},{"key":"3402_CR47","first-page":"37","volume":"62","author":"JH Xiong","year":"1994","unstructured":"Xiong JH, Ji B, Perani EG, P\u00e9tinon C, Grosset JH. Further study of the effectiveness of single doses of clarithromycin and minocycline against Mycobacterium leprae in mice. Int J Lepr Other Mycobact Dis. 1994;62:37\u201342 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8189087 . Accessed 17 Oct 2017.","journal-title":"Int J Lepr Other Mycobact Dis"},{"key":"3402_CR48","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1093\/oxfordjournals.bmb.a071952","volume":"40","author":"DA Mitchison","year":"1984","unstructured":"Mitchison DA. Drug resistance in mycobacteria. Br Med Bull. 1984;40:84\u201390 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/6442876 . Accessed 31 May 2018.","journal-title":"Br Med Bull"},{"key":"3402_CR49","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1097\/INF.0000000000000260","volume":"33","author":"FC Adler-Shohet","year":"2014","unstructured":"Adler-Shohet FC, Low J, Carson M, Girma H, Singh J. Management of Latent Tuberculosis Infection in child contacts of multidrug-resistant tuberculosis. Pediatr Infect Dis J. 2014;33:664\u20136. https:\/\/doi.org\/10.1097\/INF.0000000000000260 .","journal-title":"Pediatr Infect Dis J"},{"key":"3402_CR50","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3201\/eid2103.141313","volume":"21","author":"L Trieu","year":"2015","unstructured":"Trieu L, Proops DC, Ahuja SD. Moxifoxacin prophylaxis against MDR TB, NEW YORK, NEW YORK, USA. Emerg Infect Dis. 2015;21:500\u20133. https:\/\/doi.org\/10.3201\/eid2103.141313 .","journal-title":"Emerg Infect Dis"},{"key":"3402_CR51","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1097\/inf.0000000000000369","volume":"33","author":"JA Seddon","year":"2014","unstructured":"Seddon JA, Garcia-prats AJ, Kampmann B, Schaaf HS, Hesseling AC. Toxicity and tolerability of Fluoroquinolone-based preventive therapy for childhood contacts of multidrug-resistant tuberculosis. Pediatr Infect Dis J. 2014;33:1098\u20139. https:\/\/doi.org\/10.1097\/inf.0000000000000369 .","journal-title":"Pediatr Infect Dis J"},{"key":"3402_CR52","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/S0140-6736(82)92334-0","volume":"319","author":"SJ Yawalkar","year":"1982","unstructured":"Yawalkar SJ, Mcdougall AC, Languillon J, Ghosh S, Hajra SK, Opromolla DVA, et al. Once-monthly rifampicin plus daily dapsone in initial treatment of lepromatous leprosy. Lancet. 1982;319:1199\u2013202. https:\/\/doi.org\/10.1016\/S0140-6736(82)92334-0 .","journal-title":"Lancet"},{"key":"3402_CR53","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1136\/bmj.1.5803.765","volume":"1","author":"D Girling","year":"1972","unstructured":"Girling D, Tall R, Fox W. Adverse reactions to daily and intermittent rifampicin regimens for pulmonary tuberculosis in Hong Kong. Br Med J. 1972;1:765\u201371. https:\/\/doi.org\/10.1136\/bmj.1.5803.765 .","journal-title":"Br Med J"},{"key":"3402_CR54","first-page":"45","volume":"57","author":"DJ Girling","year":"1979","unstructured":"Girling DJ, Hitze KL. Adverse reactions to rifampicin. Bull World Health Organ. 1979;57:45\u20139 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/311712 . Accessed 11 May 2017.","journal-title":"Bull World Health Organ"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-3402-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-018-3402-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-3402-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T10:39:02Z","timestamp":1662201542000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-018-3402-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,5]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["3402"],"URL":"https:\/\/doi.org\/10.1186\/s12879-018-3402-4","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,5]]},"assertion":[{"value":"18 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethic approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"506"}}